logo-loader
viewIQ-AI Limited

Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant.
Under the agreement with US firm AI Metrics, IB will receive non-exclusive global rights to market and distribute the product, known as LSN. News here too on the brain tumour analysis platform and what other products are in the pipeline.

Quick facts: IQ-AI Limited

Price: 4.15 GBX

LSE:IQAI
Market: LSE
Market Cap: £5.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IQ-AI's David Smith explains proposed Stonechecker sale and 2020 vision

IQ-AI Ltd's (LON:IQAI) David Smith tells Proactive London's Andrew Scott why they've put their Stonechecker software business up for sale. The US FDA recently gave its approval for the product to be sold in the US and in that country alone there are an estimated 600,000 people each year who...

on 20/12/19

2 min read